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STATUS OF THE HADRONTHERAPY PROJECTS IN EUROPE 
Jean-Michel Lagniel, GANIL, Caen, France
Abstract 
Robert R. Wilson, an accelerator pioneer working with 
E.O. Lawrence at Berkeley, made the first proposal to 
treat cancer using proton beams more than 60 year ago 
(1946). In a first period, many accelerators built for 
nuclear and particle physics research have been 
progressively used to treat patients all over the word. It 
was the time of the hadrontherapy “first generation”. As it 
has been the case for the evolution of the synchrotron 
radiation sources, starting with Loma Linda in 1990, a 
“second generation” of dedicated facilities has then been 
built to treat cancer without the constraints imposed to 
“parasitic users”. The total number of patients treated 
with protons was about 10.000 in 1993 and 50.000 in 
2006, the progression looks to be exponential. 
Hadrontherapy is today part of the medical business 
landscape, several companies sell turnkey protontherapy 
centres and the fight is started for carbon centres. The 
status of some hadrontherapy projects in Europe (existing 
facilities and future projects) as well as the industrial 
aspects will be presented in this framework. 
INTRODUCTION 
The particle therapy facilities in operation are listed 
below (from PTCoG [1]). In this table the fist column is 
the first year of operation, the following are the type of 
beam (p = protons, i = ions), the location and the number 
of treated patients (see [1] for detailed information). 
1961 p Harvard, Boston, USA 9116
1969 p ITEP, Moscow, Russia 3927
1975 p St.Petersburg, Russia 1320
1979 p Chiba, Japan 145
1983 p PMRC1, Tsukuba, Japan 700
1984 p PSI-1, Villigen, Switzeland 4646
1989 p Dubna, Russia 318
1989 p Uppsala, Sweden 738
1989 p Clatterbridge, England 1584
1990 p Loma Linda, CA, USA 11414
1991 p Nice, France 3129
1991 p CPO, Orsay, France 3766
1993 p iThemba, South Africa 486
1993 p MPRI, IN, USA 220
1994 p UCSF, CA, USA 920
1994 i HIMAC, Chiba, Japan 2867
1995 P TRIUMF, Canada 111
1996 p PSI-2, Villigen, Switzeland 262
1997 i GSI, Germany 316
1998 p HMI, Berlin, Germany 829
1998 p NCC, Kashiwa, Japan 462
2001 p+i HIBMC,Hyogo, Japan 1099 +131
2001 p PMRC2, Tsukuba, Japan 930
2001 p NPTC, Boston, USA 2080
2002 p INFN-LNS, Catania, Italy 114
2002 p Wakasa, Japan 33
2003 p Shizuoka, Japan 410
2004 p WPTC, Zibo, China 270
2006 p MD And., Houston, USA 114
2006 p FPTI, Jacksonville, USA 15
At least three remarks can be made looking to this data : - 
there is nearly the same number of centres in Europe (11), 
north America (8) and Japan (8), - the proton centres 
largely dominate, - the number of constructions is rapidly 
increasing these last few years. 
This is confirmed in the table below which gives the 
expected year of first operation for hadrontherapy 
facilities in a commissioning phase, under construction or 
in a planning stage. 
2007 p RPTC, Munich, Germany 
2007/08 p PSI, Villigen, Switzerland 
2007 p NCC, Seoul, Korea 
2007 p+i HIT, Heidelberg, Germany 
2007 P+i CNAO, Pavia, Italy 
2009 p UPenn, USA 
2009 p WPE, Essen, Germany 
2009 ? p iThemba Labs, South Africa 
2009 ? p RPTC, Koeln, Germany 
2010 ? p ICPO, Orsay, France 
2010 ? p Trento, Italy 
2011 ? i Gunma Univ, Japan 
2011 ? p Chicago, USA 
2011 ? p+i PTC, Marburg, Germany 
2011 ? p+i ETOILE, Lyon, France 
2011 ? p+i Med-AUSTRON, Austria 
This non exhaustive list shows that - more than 16 
centres will enter in operation over 5 years, - Europe 
largely dominates with 11 facilities (5 in Germany), - the 
proportion of ion facilities is growing fast, - as in the 
synchrotron light source domain, there is a switch form a 
first generation (parasitic use of the beam) to the second 
generation of dedicated facilities (PSI, ICPO for 
example), - a large majority of these new facilities (p and 
i) are or will be built as “turnkey facilities” by specialized 
Companies. (Rieneker PTC, Marburg, ETOILE…). 
MEDICAL BENEFIT OF 
HADRONTHERAPY 
Particles versus Photons 
It is well known that the concentration of energy 
deposition of ions in a localized Bragg pick (Fig. 1) gives 
a better ballistic precision compared to photons. The 
different treatment must nevertheless be compared in term 
of better preservation of the healthy tissues and “Organ at 
Risk” in the tumor vicinity. The recent progress done with 
IMRT (Intensity Modulated Radio-Therapy), Cyber 
Knifes … which compensate the ballistic drawback of the 
photons by a better geometric and quantitative dose 
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distribution, as well as the fact that photons and protons 
have the same radiobiological efficiency, leads to a 
situation where there is no clear advantage of protons 
versus photons for most of the treatments. 
 
Fig. 1:  Dose deposition of photons, protons and carbon 
ions in water. 
Carbons versus Protons 
Concerning the ballistic precision, carbon ions have the 
disadvantage of dose deposition after the Bragg pick due 
to the ion fragmentation (Fig. 2). Nevertheless, this 
drawback is largely compensated by a much lower radial 
diffraction (Fig. 3), a diffraction which penalizes protons 
for the treatment of deep-seated tumours. 
 
Fig. 2:  Example of dose deposition of protons and carbon 
ions in water (Spread Out Bragg Pick). 
2,5 cm  
Fig. 3:  Radial diffusion of protons (upper pictures) 
 and carbon ions in water (E Blakeley LBL). 
Photons / Protons / Carbons medical benefits 
The decisive advantage of ions compared to photons 
and protons comes from their higher Linear Energy 
Transfer (LET) and Radio Biological Effectiveness 
(RBE). The RBE value is fixed at 1 for photons, it is 
around 1.1 for protons and reach 3.0 … 5,0 and above for 
carbon ions in the tumours depending of their 
composition. This property is illustrated on Fig. 4 which 
shows a clear advantage for the carbon ions in case of 
radio-resistant tumours representing approximately 10% 
of the total number of radiotherapies (meaning that the 
need is around 1 centre for 15 million inhabitants). 
 
Fig. 4:  Comparison of efficient dose deposition 
(Gy Equivalent) of protons and carbon ions for resistant 
and sensitive tumours and normal tissues surrounding the 
tumour (M. Scholz GSI). 
SOME HADRONTHERAPY FACILITIES 
IN EUROPE 
Looking to the list of hadrontherapy centers given in 
the first section of this paper, it is obvious that an 
exhaustive description of the European centers cannot be 
envisaged here. After the medical arguments developed in 
the previous sections, the choice has been made to focus 
our attention on the development of carbon therapy. 
Pioneer work at GSI 
With HIMAC in Japan, GSI is the place where a 
decisive pioneer work has been done for carbon-therapy. 
First of all, the GSI Biophisik Group has done the 
research works on the Relative Biological Effectiveness 
(RBE) of the ions and the links between RBE and DNA 
damages, repairing and non-repairing cells. The “Local-
Effect-Model” (cell survival) has then been built and 
verified making in-vitro and in-vivo experiments. Finally, 
the RBE modelling has been validated and a Treatment 
Planning System (TPS) has been constructed.GSI makes 
also decisive technical developments to improve the 
quality of the treatments. The most famous is the raster 
scanning (spot-scanning) technique which allows a nearly 
perfect dose deposition in the tumour with an optimal 
preservation of the surrounding tissues (Fig 5). This 
“active” technique is more precise than the “passive” one 
based on the use of collimators and energy degraders. It 
has been use to treat more than 300 patient at GSI and is 
also used at PSI. 
HIT Heidelberg, Germany 
After a long period of technical work and discussions, 
the work done at GSI has lead to the construction of a 
dedicated heavy ion therapy centre at Heidelberg (Fig. 6). 
GSI made the accelerator, beam lines (2 horizontal) and 
rotating gantry designs (Fig. 7 and 8) [2,3]. The first turn 
in the synchrotron has been achieved in February this 
year, the commissioning of the facility in progress. 
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Fig. 5:  The spot-scanning technique developed at GSI, 
schematic view of the hardware. 
 
 
Fig. 6:  HIT Heidelberg Centre, photo of the building (up) 
and schematic view of the injector, synchrotron, 
horizontal beam lines and rotating gantry (down). 
 
Fig. 7:  Photo of the HIT Heidelberg gantry, the total 
rotating weight is ≈600 tons, the weight of the last 90° 
bending magnet is ≈60 tons. 
CNAO, Pavia, Italy 
The realization of the Italian National Centre for 
Oncological Hadrontherapy (CNAO from the Italian 
acronym) started in September 2002 with the final design. 
The basic design of the accelerator and beam lines comes 
from the Proton-Ion Medical Machine Study (PIMMS) 
done at CERN from 1996 to 1999 with the TERA group 
who was the promoter of this project since 1992. This 
carbon facility (Fig. 8) is equipped with 3 treatment 
rooms in a first phase (2 with horizontal beams, 1 with 
horizontal and vertical beams) and a room for QA and 
experimental researches. The goal is to treat 3000 patients 
per year. The buildings construction is done to allow an 
extension housing a carbon rotating gantry. 
 
 
Fig. 8:  CNAO (Pavia, Italy) carbon therapy Centre, 
schematic view with the synchrotron and beam lines (up) 
and photo of the building (February 2007, down). 
ETOILE, Lyon, France 
The construction of ETOILE, the French National 
Hadrontherapy Centre, has been approved by the French 
ministries of health and research in May 2006. This 
carbon therapy centre will be built in the framework of a 
Public – Private Partnership : - the Private Partner will 
finance and built the facility, - the facility will be the 
property of the Private Partner who will operate and 
maintain the facility (technical operation), - The medical 
team (Public Partner) will rent the beam time. The Private 
Partner selection will be made before end-2008. 
HADRONTHERAPY IS A BUSINESS 
Like radiotherapy… and therapy… hadrontherapy is 
now a business. The first table in the introduction shows 
that 15 “built by industry” protontherapy centres are 
running today (11 constructed by European companies, 4 
by Japanese companies). The second table shows an 
acceleration of the phenomena, for protons but also for 
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carbons (Marburg, ETOILE and MedAustron for 
example). 
IBA 
With 9 centers in operation and a large majority of the 
new orders, IBA is the world leader in protontherapy 
today. The offer is based on the IBA proteus 235 compact 
normal-conducting cyclotron (Fig. 9), horizontal beam 
lines and rotating gantries for passive treatments (an 
active scanning system is under study). IBA is also 
proposing a challenging carbon facility scheme based on 
a supraconducting isochronous cyclotron accelerating 
Q/M = 1/2 ions at 400 MeV/U (Fig. 10). 
 
Fig. 9:  IBA proteus 235 compact normal-conducting 
cyclotron. 
 
Fig. 10: IBA proposition of carbon therapy centre. 
From the left to the right : 400 MeV/U carbon 
superconducting cyclotron, proton cyclotron, proton 
gantry, horizontal fixed beam treatment room, 
 two proton / carbon gantries and one research area. 
ACCEL 
Accel participates to the construction of the PROSCAN 
facility at PSI and Rinecker Proton Therapy Center 
(RPTC) in Munchen. These offers based on a very 
compact supraconducting cyclotron (Fig. 11) include the 
beam lines and the rotating gantries. 
For the PROSCAN proton therapy centre at PSI 
(Fig. 12), the goal is to switch from the first generation 
(SINQ parasitic use) to a second generation with the 
ACCEL supraconducting cyclotron, new beam lines and a 
new gantry (the CPO in France is in a similar situation but 
IBA has been chosen). March 22, 2007, a PSI 
communicate announced that “Clinicians at the Paul 
Scherrer Institute in Switzerland have begun clinical 
treatments using the world's first commercial 
supraconducting cyclotron for routine medical use”. 
 
 
Fig. 11:  Accel supraconducting cyclotron. 
 
Fig. 12:  Scheme of the PROSCAN facility at PSI. 
The RPTC which is in the commissioning phase will 
work with 4 gantries and one horizontal fixed beam line, 
the present situation is the following: 
• Extracted beam up to 1µA 
• Beam energy variable from 70 to 250 MeV 
• Extraction efficiency of cyclotron 70 % 
• Routine beam delivery to gantry room G1 
• Scanning systems operable in G1 
• Patient positioning / verification accepted by TÜV 
• Software tools for G1 completed (incl. the TPS) 
• Successful test of ~1 % dose conformity by technical 
expert of approving authority 
ACCEL is part of Varian Medical Systems since the 
beginning of this year. The combination of Varian’s 
expertise in image-guided radiation therapy (IGRT), 
treatment planning, information systems, clinical 
workflow, manufacturing, service and distribution with 
the ACCEL’s proton therapy technology and expertise 
allows to offer a fully integrated proton treatment system 
from a single company. 
SIEMENS 
SIEMENS Medical Solutions has an industrial offer of 
turnkey proton plus carbon facilities thanks to a 
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knowledge-transfer & licenses from GSI (synchrotron and 
raster scanning technology, treatment optimization 
including the biological effects of ions, treatment 
planning software). For the construction of the new 
facilities, Danfysik is the exclusive supplier of accelerator 
systems for SIEMENS (from the sources up to the 
treatment rooms), they propose a standardized solution 
for proton and carbon therapy in one system. 
But accelerator and beam lines are just one component 
of the hadrontherapy centre. The SIEMENS standardized 
solutions also include : 
- Scanning and beam monitoring systems, 
- Gantries, robotic tables for patient positioning in the 
treatment rooms, 
- Patient transport systems, 
- Imaging (diagnostic and position verification), 
- Treatment Planning System, 
- IT (oncology information system, administration, 
archiving…), 
- Project management, 
- Technical operation and maintenance. 
The first turnkey facility built by SIEMENS is the 
Marburg carbon therapy centre. Fig. 13 shows an 
optimized use of the surfaces for the patient flow. 
 
 
Fig. 13: Schematic view of the Marburg centre. 
SUMMARY 
Hadrontherapy is born thanks to the developments 
made in the field of fundamental physics (Pioneer work at 
Berkeley, Uppsalla… Fermi for Loma Linda… Chiba, 
GSI…). Today, the accelerator technologies are optimized 
in terms of performance and cost for nearly all the 
components and hadrontherapy has switched in the 
business domain with a hard industrial competition. 
Electron, proton and heavy ion accelerators for medical 
applications (15 000 following Ugo Amaldi) are now built 
(and sometimes operated) by industry. Several companies 
have demonstrated the ability to built very performing 
accelerator turnkey facilities with medical assurance 
quality standards for the best price. Is it a lesson for the 
construction of accelerator facilities for fundamental 
research in the future ? 
The involvement of Academic Laboratories is then 
more and more complex, even if some groups are still 
getting some money to study exotic concepts with few 
chances to obtain better performances at lower cost. One 
of the exceptions could result from the work done on 
carbon gantries (Fig. 14) using superconducting magnets. 
The goal must be to decrease the cost, not to decrease the 
weight or the size ! 
 
 
Fig. 14: Schematic scheme of a rotating gantry. 
How can we make it cheaper ? 
The highest R&D priorities are not strictly related to 
accelerators, they deal with – the Treatment Planning 
Systems (error tolerance, better taking into account of the 
RBEs, Monte Carlo simulations), - fast and accurate beam 
monitoring systems, - ergonomic and accurate patient 
positioning system, - respiration gating (moving targets), - 
dose homogeneity (repainting), - imaging and online dose 
monitoring (online PET for QA …). 
From the medical benefit of hadrontherapy point of 
view, protontherapy is in competition with the new 
photon technologies (new IMRT systems). The medical 
experts are not unanimous; it seems that active spot 
scanning protontherapy gives better results than MRT for 
several specific cases. On the other hand, the higher 
ballistic precision and RBE give a clear medical 
advantage to carbon for the treatment of radio-resistant 
tumours. This “market” is estimated to ~ 10% of the total 
radiotherapy “market” (1 facility for ~15 M inhabitants). 
Finally, impossible to end this paper without saying that 
hadrontherapy is the most motivating “application of 
accelerators”. Physicists interested to go further in this 
domain must visit the PTCoG web site and follow the 
links… and attend the PTCoG meetings which are by far 
the most interesting on this topic. 
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